medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2022, Number 1

<< Back Next >>

Rev Latin Infect Pediatr 2022; 35 (1)

Late-onset childhood sarcoidosis with multiorgan involvement. Report of two cases and review of the literature

Rodríguez HR, Carbajal RL, Rojas MCM, Uña FA, Gutiérrez MG, Barrios SE

Language: Spanish
References: 58
Page: 30-45
PDF size: 600.42 Kb.


ABSTRACT

Introduction: Sarcoidosis is a systemic disease of unknown etiology. It occurs rarely in childhood. It is characterized by fever, multiorgan involvement, especially pulmonary, cutaneous, neurological, ocular, renal, articular, lymphadenopathy, hepatomegaly and splenomegaly. Clinical case: We report two cases of late-onset infantile sarcoidosis, whose diagnosis was confirmed by histopathological study of the kidney in case 1 and of the skin in case 2. Both patients had systemic manifestations with predominance of pulmonary alterations, uveitis and hypercalcemia, hypercalciuria. They received initial treatment with steroid and mycophenolate mofetil without adequate response. Conclusions: It is important to consider the diagnosis of sarcoidosis in patients with diffuse lung damage, uveitis, facial palsy, erythema nodosum, hypercalcemia and elevated serum angiotensin-converting enzyme levels. The complexity of this disease and the wide range of symptoms with which it may present make an interdisciplinary approach to the patient essential to assess multiple organ involvement and the timely initiation of therapy with steroids and methotrexate, in order to prevent disease progression.


REFERENCES

  1. Rosé CD, Wouters C. Pediatric sarcoidosis. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, editors. Textbook of pediatric rheumatology. 7th edition. Philadelphia: Elsevier, Inc.; 2016. pp. 517-525.

  2. Sharma OP. Sarcoidosis: a historical perspective. Clin Dermatol. 2007; 25: 232-241.

  3. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999; 160 (2): 736-755.

  4. Fernández FE. Epidemiología de la sarcoidosis. Arch Bronconeumol. 2007; 43: 92-100.

  5. Gedalia A, Khan TA, Shetty AK, Dimitriades VR, Espinoza LR. Childhood sarcoidosis: Louisiana experience. Clin Rheumatol. 2016; 35 (7): 1879-1884.

  6. Rybicki BA, Lannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007; 28: 22-35.

  7. Cox CE, Davis-Allen A, Judson MA. Sarcoidosis. Med Clin North Am. 2005; 89: 817-828.

  8. Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015; 147: 438-449.

  9. Hoffmann A, Milman N, Byg K. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004; 93: 30-36.

  10. Caso F, Costa L, Rigante D, Vitale A, Cimaz R, Lucherini OM et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev. 2014; 13: 1220-1229.

  11. Cruz AI, Barón LS, Garrido GC, Velázquez SJ. Sarcoidosis pulmonar. Rev Chil Pediatr. 2011; 82 (6): 535-541.

  12. Rodríguez CMA, Castellanos IAA, García GPE, Sánchez TT. Sarcoidosis cutáneo-pulmonar: comunicación de dos casos y revisión bibliográfica. Dermatol Rev Mex. 2009; 53: 299-302.?

  13. Violante N, Reyes E, Honda S, García A, Orozco R. Sarcoidosis cutánea en tres pacientes mexicanos: análisis clínico-patológico de las variantes papular, nodular y en placa. Dermatol Rev Mex. 1997; 41: 28-33.

  14. Arevalo-López A, Macotela-Ruiz E. Sarcoidosis (intra y extratorácica): a propósito de un caso mexicano. Gac Med Mex. 1991; 127: 411-417.

  15. Julián-González RE, Saez-de-Ocariz M, Orozco-Covarrubias L, Durán McKinster C, Ruiz-Maldonado R. Sarcoidosis de inicio temprano. Rastreo de casos nuevos en pacientes previamente diagnosticados con artritis idiopática juvenil. Dermatol Pediatr Latinoam. 2012; 10: 58-63.

  16. Zamora-Chávez A, Sadowinski-Pine S, Serrano Bello C, Velázquez-Jones L, Saucedo-Ramírez J, Palafox-Flores J et al. Sarcoidosis en la infancia. Una rara enfermedad sistémica. Bol Med Hosp Infant Mex. 2016; 73: 117-128.

  17. Vega-Cornejo G, Ayala-Buenrostro P. Sarcoidosis laríngea infantil: presentación de un caso clínico. Reumatol Clin. 2019; 15: e102-e104.

  18. Nathan N, Marcelo P, Houdouin V, Epaud R, Blic J, Valeyre D et al. Lung sarcoidosis in children: update on disease expression and management. Thorax. 2015; 70: 537-542.

  19. Rotsinger JE, Drake WP. Sarcoidosis: unknown etiology and genetic predisposition provides therapeutic challenges. J Pulm Respir Med. 2014; 4: 190. Available in: http://dx.doi.org/10.4172/2161-105X.1000190

  20. González Fernández MI. Sacoidosis pediátrica. Protoc Diagn Ter Pediatr. 2020; 2: 401-412.

  21. Jain R, Yadav D, Puranik N, Guleria R, Jin JO. Sarcoidosis: causes, diagnosis, clinical features, and treatments. J Clin Med. 2020; 9: 1081. Available in: https://doi.org/10.3390/jcm9041081

  22. Du Bois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med. 2003; 253: 4-17.

  23. Wouters CH, Maes A, Foley KP, Bertin J, Rose CD. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol. 2014; 12: 33.

  24. Thomeer M, Demedts M. Predictive value of CD4/CD8 ratio in bronchoalveolar lavage in the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997; 14 Suppl 1: 36.

  25. Welker L, Jorres RA, Costabel U, Magnussen H. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J. 2004; 24: 1000-1006.

  26. Díaz AT, Morales CW, Lozano NL, Plata OJ, Zárate TL. Sarcoidosis sistémica: un reto diagnóstico en pediatría. Reporte de un caso. Arch Argent Pediatr. 2016; 114: e323-e328.

  27. Grutters JC, Fellrath JM, Mulder L, Janssen R, van den Bosh JM, van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest. 2003; 124: 186-195.

  28. Bachiller-Corral J. Otras causas de hipercalcemia. En: Sociedad Española de Reumatología. Manual de enfermedades óseas. Madrid: Editorial Médica Panamericana, S.A.; 2010. pp. 143-148.

  29. González-Lamuño D. Hipercalciuria. Pediatr Integral. 2013; 17: 422-432.

  30. Marginean CO, Melit LE, Grigorescu G, Puiac C, Simu I. Hypercalcemia, an important puzzle piece in uncommon onset pediatric sarcoidosis-a case report and a review of the literature. Front Pediatr. 2020; 8: 497. doi: 10.3389/fped.2020.00497.

  31. Milman N, Hoffmann AL. Childhood sarcoidosis: long-term follow-up. Eur Respir J. 2008; 31: 592-598.

  32. Giuffrida TJ, Kerdel FA. Sarcoidosis. Dermatol Clin. 2002; 20: 435-447.

  33. Gokdemir Y, Ersu R, Karadag B, Karakoc F, Kiyan G, Kaya H et al. Sarcoidosis infantil. Un caso clínico infrecuente. Arch Argent Pediatr. 2013; 111: e113-e116.

  34. Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers. 2019; 5: 45.

  35. Nathan N, Sileo C, Calender A, Pacheco Y, Rosental PA, Cavalin C et al. Paediatric sarcoidosis. Paediatr Respir Rev. 2019; 29: 53-59. doi: 10.1016/j.prrv.2018.05.003.

  36. Kendig EL, Niitu Y. Sarcoidosis in Japanese and American children. Chest. 1980; 77: 514-516.

  37. Fretzayas A, Moustaki M, Vougiouka O. The puzzling clinical spectrum and course of juvenile sarcoidosis. World J Pediatr. 2011; 7: 103-110. doi: 10.1007/s12519-011-0261-0.

  38. Alawdah L, Nahari A, Alshahrani D, Fagih M, Ghazi S, Al-Hussaini A. Pediatric gastrointestinal sarcoidosis: Successful treatment with infliximab. Saudi J Gastroenterol. 2016; 22: 391-395. doi: 10.4103/1319-3767.191146.

  39. Sengül OK, Akkelle BS, Volkan B, Tutar E, Celikel CA, Ertem D. Gastrointestinal sarcoidosis presenting with malabsorption at an early age. Turk Pediatri Ars. 2020; 55: 441-444. doi: 10.14744/TurkPediatriArs.2019.93274.

  40. Lim V, Clarke BL. Coexisting primary hyperparathyroidism and sarcoidosis cause increased angiotensin-converting enzyme and decreased parathyroid hormone and phosphate levels. J Clin Endocrinol Metab. 2013; 98: 1939-1945.

  41. Seve P, Pacheco Y, Durupt F, Jamilloux Y, Gerfaud-Valentin M, Isaac S et al. Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells. 2021; 10 (4): 766. doi: 10.3390/cells10040766.

  42. Dobrin RS, Vernier RL, Fish AL. Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granulomas and anterior uveitis. A new syndrome. Am J Med. 1975; 59: 325-333.

  43. Agarwal R, Kanaujia V, Mishra P, Sharma K. Tubulointerstitial nephritis and uveitis syndrome: our experience. Oman J Ophthalmol. 2020; 13 (2): 89-91.

  44. Jamilloux Y, Kodjikian L, Broussolle C, Seve P. Sarcoidosis and uveitis. Autoimmun Rev. 2014; 13 (8): 840-849. doi: 10.1016/j.autrev.2014.04.001.

  45. Kansal V, Dollin M. Ocular involvement in sarcoidosis. CMAJ. 2017; 189 (16): E609. doi: 10.1503/cmaj.160569.

  46. Herbort CP, Rao NA, Mochizuki M; members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009; 17 (3): 160-169.

  47. Chavarriaga-Restrepo A, López Amaya JE, Mesa Navas MA, Velázquez Franco CJ. Sarcoidosis: muchas caras, una enfermedad. Revisión narrativa de la literatura. Iatreia. 2019; 32 (3): 191-203. doi 10.17533/udea.iatreia.

  48. Lynch JP 3rd, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med. 2014; 35: 372-390. doi: 10.1055/s-0034-1376889.

  49. Rao R, Dimitriades VR, Weimer M, Sandlin C. Neurosarcoidosis in pediatric patients: a case report and review of isolated and systemic neurosarcoidosis. Pediatr Neurol. 2016; 63: 45-52. doi: 10.1016/j.pediatrneurol.2016.05.018.

  50. Kidd DP. Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results. J Neurol. 2018; 265: 1906-1915. doi: 10.1007/s00415-018-8928-2.

  51. Gardner G, Shoback D. Endocrinología básica y clínica de Greenspan. 9a ed. México: McGraw-Hill; 2012. p. 95.

  52. Valeyre D, Bernaudin JF, Uzunhan Y, Kambouchner M, Brillet PY, Soussan M et al. Clinical presentation of sarcoidosis and diagnostic work-up. Semin Respir Crit Care Med. 2014; 35: 336-351. doi: 10.1055/s-0034-1381229.

  53. Govender P, Berman JS. The diagnosis of sarcoidosis. Clin Chest Med. 2015; 36: 585-602. doi: 10.1016/j.ccm.2015.08.003.

  54. Carmona EM, Kalra S, Ryu JH. Pulmonary sarcoidosis: diagnosis and treatment. Mayo Clin Proc. 2016; 9: 946-954. doi: 10.1016/j.mayocp.2016.03.004.

  55. Gerke AK. Treatment of sarcoidosis: a multidisciplinary approach. Front Immunol. 2020; 37: 425-432. doi: 10.3389/fimmu.2020.545413.

  56. Kahlmann V, Janssen Bonás M, Moor CC, van Moorsel CHM, Kool M, Kraaijvanger R et al. Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. BMC Pulm Med. 2020; 20: 271. doi: 10.1186/s12890-020-01290-9.

  57. McKeever A, Cox A, Garnett M, Cunniffe NG. Hydrocephalus as the first presenting symptom of neurosarcoidosis in two patients: a diagnosis more forthcoming in the context of systemic disease. BMJ. 2019; 12: e229903. doi: 10.1136/bcr-2019-229903.

  58. Kobak S. Catch the rainbow: prognostic factor of sarcoidosis. Lung India. 2020; 37: 425-432. doi: 10.4103/lungindia.lungindia_380_19.




2020     |     www.medigraphic.com